Premium
MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B‐cell lymphomas
Author(s) -
Liggins Amanda P.,
Cooper Christopher D. O.,
Lawrie Charles H.,
Brown Philip J.,
Collins Graham P.,
Hatton Chris S.,
Pulford Karen,
Banham Alison H.
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06680.x
Subject(s) - diffuse large b cell lymphoma , germinal center , lymphoma , zinc finger , biology , cancer research , antibody , pathology , messenger rna , gene , b cell , microbiology and biotechnology , medicine , immunology , transcription factor , genetics
Summary The OX‐TES‐4 antigen originally elicited an antibody response in 50% of diffuse large B‐cell lymphoma (DLBCL) patients but not in control subjects. OX‐TES‐4 is encoded by a novel gene, MORC4 , located at chromosome Xq22.3. The MORC4 protein contains a HATPase‐c domain, CW zinc finger motif, nuclear localisation signals and a nuclear matrix‐binding domain, together with a coiled‐coil region. MORC4 mRNA is widely expressed at low levels in normal tissues, showing highest expression levels in placenta and testis. mRNA levels were increased in non‐germinal centre‐derived DLBCL and Hodgkin lymphoma cell lines, compared with germinal centre‐derived DLBCL cell lines and normal B cells. Nineteen DLBCL patients (66%) expressed significantly higher levels of MORC4 mRNA than normal B cells ( P = 0·0031). The differential expression of MORC4 identifies this molecule as a potential lymphoma biomarker, whose overexpression may contribute to the immunological recognition of MORC4 by a subgroup of DLBCL patients.